Millendo Therapeutics (NASDAQ:MLND) initiated with Outperform rating and $26 (141% upside) at Oppenheimer.
Viking Therapeutics (NASDAQ:VKTX) initiated with Neutral rating and $12 (46% upside) price target at Oppenheimer.
Precision BioSciences (NASDAQ:DTIL) initiated with Buy rating and $21 (53% upside) price target at H.C. Wainwright.
Bio-Path Holdings (NASDAQ:BPTH) initiated with Buy rating and $28 (117% upside) at H.C. Wainwright. Shares up 11% premarket.
Syros Pharmaceuticals (NASDAQ:SYRS) resumed with Buy rating and $17 (126% upside) price target at Roth Capital.
LabCorp (NYSE:LH) upgraded to Neutral at BofA/Merrill Lynch.
Agilent (NYSE:A) downgraded to Neutral with a $76 (8% upside) price target at BofA/Merrill Lynch.
Allergan (NYSE:AGN) downgraded to Market Perform with a $180 (8% upside) price target at Bernstein.
QIAGEN N.V. (NYSE:QGEN) downgraded to In Line with a $41 (2% upside) price target at Evercore ISI. Shares down 1% premarket.
Thermo Fisher Scientific (NYSE:TMO) downgraded to Buy with a $315 (9% upside) price target at BofA/Merrill Lynch.
Adamis Pharmaceuticals (NASDAQ:ADMP) downgraded to Sell with a $1.10 (25% downside risk) price target at B. Riley FBR. Shares down 4% premarket.
Kindred Biosciences (NASDAQ:KIN) downgraded to Neutral with an $8.50 (9% upside) price target at B. Riley FBR.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.